Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio ...Middle East

- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development...

Read More Details
Finally We wish PressBee provided you with enough information of ( Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio )

Also on site :

• Barbra Streisand Reveals Jaw-Dropping Details of Scandalous Proposal from Hollywood Icon!
• Uno de los médicos acusados ​​de suministrar ketamina a Matthew Perry acepta declararse culpable, según muestra el documento
• In Q1 2025, enterprise SaaS M&A deal count hit 210, according to PitchBook